Abstracts - PAGE Meeting (Population Approach Group Europe)

← Back to filters

Abstracts (45)

I-015Flavie Audy

Modeling Targeted Radionuclide Therapy: General Approach to Optimize Dose Selection

Wednesday 10:30-12:00

I-018Idris Bachali Losada

Towards precision modeling for accurate tumour growthprediction leveraging multiple modalities

Wednesday 10:30-12:00

I-030Massinissa Beldjenna

Beyond averages: Why capturing cellular variability matters in viral dynamic modeling.

Wednesday 10:30-12:00

I-037Robert Bies

Multi-Objective Optimization for Population Pharmacokinetic Model Selection: Evaluating NSGA-III Performance

Wednesday 10:30-12:00

I-059Xiaomei Chen

Computer-intensive model-building explorations to facilitate understanding at the levels of methodology, implementation, and application

Wednesday 10:30-12:00

I-067Lorenzo Cifelli

PKPD modeling for rapid dose selection with IMPRES-M, a novel smoothing approach.

Wednesday 10:30-12:00

I-069Neva Coello

Enhancing Pharmacometric Analyses with Estimand Framework and Causal Inference

Wednesday 10:30-12:00

I-073James Craig

Multi-objective Optimization for Population Pharmacokinetic (PopPK) Model Selection Using NSGA-II and pyDarwin

Wednesday 10:30-12:00

I-102Laurence Dodd

Integration of a Novel First-Order Release Z-Factor Dissolution Model with Global Sensitivity Analysis to Guide Formulation Development using Physiologically-Based Biopharmaceutics in OSPSuite v12

Wednesday 10:30-12:00

I-112Jeroen Elassaiss-schaap

Extension of IMPRES-M, the smoothing impulse-response PK-PD framework, to population pharmacokinetic analysis

Wednesday 10:30-12:00

II-006Elisa Fevola

A trimer-based MABEL approach for the First-In-Human starting dose selection of T-cell Engagers

Wednesday 15:30-17:00

II-020Daniel Glazar

Patient-reported outcomes to inform patient-specific tumor growth inhibition parameters

Wednesday 15:30-17:00

II-026Gordon Graham

Continuous-time Markov models: Investigation into the use of Stan and msm for fitting disease progression models for EDSS in multiple sclerosis

Wednesday 15:30-17:00

II-030Boris Grinshpun

Simulation with Parameter Uncertainty using NMsim

Wednesday 15:30-17:00

II-034Yuchen Guo

Joint distribution modelling of drug metabolizing enzymes and transporters expression for PBPK-driven virtual patient simulation

Wednesday 15:30-17:00

II-053Ludvig Jakobsson

A simulation-based evaluation of a hidden Markov model to characterize disease transitions using frequently sampled spirometry data

Wednesday 15:30-17:00

II-062Jie Ju

Using a smoother approach IMPRES-M to estimate parameters of biomarkers in multi-layered turnover networks

Wednesday 15:30-17:00

II-065Venetia Karamitsou

A pipeline for generating large virtual dog populations to predict preclinical drug-induced liver injury

Wednesday 15:30-17:00

II-068Csaba Katai

On the coupling between a basic FcRn mechanism and target-mediated drug disposition of antibodies—an asymptotic analysis in the high binding affinity limit

Wednesday 15:30-17:00

II-072Svenja Kemmer

Towards a translational QSP modeling approach to predict bone marrow toxicity

Wednesday 15:30-17:00

II-084Konstantina Koliopoulou

AutoML and Residual Error Meta-Modeling in Model-Informed Drug Development: A Case Study of Pharmaceutical Pellets.

Wednesday 15:30-17:00

II-099Alexandra Lavalley-morelle

Efficient exposure-response analysis for time-to-event endpoints: beyond the use of time-static exposure metrics

Wednesday 15:30-17:00

III-019Peng Man

Stepwise Covariate Modeling Acceleration Using Individual Uncertainty Adjusted Linear Covariate Screening Methods

Thursday 9:50-11:45

III-025Camille Massaux

Physiologically based Pharmacokinetic model implementations are different in available Software platforms and their choice can significantly influence the reproduction of results and related Regulatory and clinical decisions: Case of oral contraceptives

Thursday 9:50-11:45

III-029Francois Mercier

{jmpost}: An R package for Bayesian joint TGI-OS models

Thursday 9:50-11:45

III-040Marcel Mohr

Prediction of Drug-Induced Hematotoxicity by an Integrated Clinical-Experimental-Computational Human Hematopoiesis Systems Toxicology Model

Thursday 9:50-11:45

III-057Rikard Nordgren

A modified Bayesian information criterion (mBIC) with multiple testing correction for population pharmacokinetic model building

Thursday 9:50-11:45

III-073Seongwon Park

Meta-based External Validation Through Model Integration Incorporated Prior Information: Application of Tenofovir Alafenamide and Tenofovir

Thursday 9:50-11:45

III-079Diego Perazzolo

Data-Driven Approach to Covariate Selection in PopPK: Integrating Variational Autoencoders (VAE) and LASSO Regression

Thursday 9:50-11:45

III-087Morgane Philipp

From standard to high-dimensional covariate model building: assessing covariate clinical relevance determination using covariate selection approaches (SCM, SCM+) and full modeling methods (FFEM, FREM) in population PK analyses

Thursday 9:50-11:45

III-088Matthias Pierre

Implementation and comparison of six algorithms for automated model building in Monolix: two simulation studies and ten applications

Thursday 9:50-11:45

III-100Alessandro Ravoni

Integrating an Agent-Based Immune Model with PBPK/PKPD to Simulate Antitubercular Treatment in Humans

Thursday 9:50-11:45

IV-001Mark Sale

Announcement of Machine Learning Benchmarking

Thursday 15:00-16:45

IV-004Aymara Sancho Araiz

Model reductions of a physiologically-based pharmacokinetic model for intestinal and hepatic first pass metabolism: towards derivation of a generalized bioavailability model using midazolam as case example

Thursday 15:00-16:45

IV-017Raju Prasad Sharma

A Minimal Physiologically based pharmacokinetic Framework Incorporating Antigen Shedding Dynamics for Optimizing Immuno-Oncology Therapies

Thursday 15:00-16:45

IV-018Sanaya Shroff

NMsim: Seamless NONMEM Simulation Platform in R

Thursday 15:00-16:45

IV-053Yaroslav Ugolkov

Quantitative systems pharmacology model of B-cell immune response

Thursday 15:00-16:45

IV-056Séverine Urdy

PBPK modeling and simulation of the pharmacokinetics of an antibody drug conjugate in a patient population of phase I clinical trials

Thursday 15:00-16:45

IV-061Hidde van de Beek

Aggregate data modeling in R: a new method for fitting pharmacometrics models to summary-level data

Thursday 15:00-16:45

IV-062Stefan Van Den Berg

One model to rule them all? A meta-analysis of therapeutic antibody population PK models.

Thursday 15:00-16:45

IV-069Abraham Vaquero Castro

AI/ML algorithm for clinical data reconstruction: Turning AD into IPD.

Thursday 15:00-16:45

IV-070Sergei Vavilov

Model-based reproduction of receptor-targeting antibody pharmacodynamics allows to identify ligand turnover parameters

Thursday 15:00-16:45

IV-082Tianqi Wang

Leveraging Machine Learning to Decode Polymeric Long-Acting Injectables and Predict Their Performance

Thursday 15:00-16:45

IV-093Daniel Wojtyniak

Parameter Significance Test Using Mixture Models (PaSTUM) allowing Type-1 Error Control for Exposure Response Modelling

Thursday 15:00-16:45

IV-107Renwei Zhang

Model-based meta-analysis of combination drug effects to evaluate drug effect independency and interaction effects

Thursday 15:00-16:45